2020
Overview
Recombinant vector vaccines are vaccines that use a harmless or weakened carrier virus or bacterium, modified through recombinant DNA technology, to deliver genetic instructions for a target antigen into the body. Once inside cells, the vector prompts production of the antigen, which trains the immune system to recognize and defend against the disease-causing pathogen without exposure to the pathogen itself. This platform is used against a range of infectious diseases and is valued for its ability to generate both antibody and cellular immune responses. As a topic within Current Viruses and Treatment Methodologies, recombinant vector vaccines sit alongside the broader study of viral pathogens, immunization strategies, and antiviral treatment approaches covered by the journal. Vaccine development against emerging viruses, including the rapid response to COVID-19, has highlighted how different vaccine platforms, their underlying technologies, and their development challenges shape public-health preparedness. This page gathers peer-reviewed, open-access research relevant to vaccine science and virology, providing context for how recombinant vector approaches fit within the wider landscape of vaccine design and infectious-disease control.
Research published in this journal
2 peer-reviewed articles, ranked by relevance. Each links to its DOI.
2021
How this research is being cited
The 2 articles above have been cited 1 time in the scholarly literature. Citation data via OpenAlex and Crossref, updated Oct 2025.
-
2020 · Eurasian journal of veterinary sciences
A sample of recent works citing this journal's research on Recombinant Vector Vaccines, linking to each citing work.